[
  {
    "ts": null,
    "headline": "UBS Turns More Bullish on Gilead Sciences, Inc. (GILD) Amid Positive Pharma Sector Outlook",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is among the most profitable healthcare stocks to buy. On January 26, UBS lifted the price target on Gilead Sciences, Inc. (NASDAQ:GILD) from $145 to $155 and maintained a Buy rating, according to TheFly. Slightly below the consensus 1-year high price target, the revised target implies nearly 12% upside. From appealing […]",
    "url": "https://finnhub.io/api/news?id=08092c8847dc4331591d3b6a821ef76af1d06cc703487bffd50098c0792bea17",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769880952,
      "headline": "UBS Turns More Bullish on Gilead Sciences, Inc. (GILD) Amid Positive Pharma Sector Outlook",
      "id": 138316677,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is among the most profitable healthcare stocks to buy. On January 26, UBS lifted the price target on Gilead Sciences, Inc. (NASDAQ:GILD) from $145 to $155 and maintained a Buy rating, according to TheFly. Slightly below the consensus 1-year high price target, the revised target implies nearly 12% upside. From appealing […]",
      "url": "https://finnhub.io/api/news?id=08092c8847dc4331591d3b6a821ef76af1d06cc703487bffd50098c0792bea17"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results",
    "summary": "Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...",
    "url": "https://finnhub.io/api/news?id=d4ea090ef83c171d1c4004ca3255f6880ec9b3487f4ff06f5b12526ee30a47cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769833118,
      "headline": "Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results",
      "id": 138313022,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...",
      "url": "https://finnhub.io/api/news?id=d4ea090ef83c171d1c4004ca3255f6880ec9b3487f4ff06f5b12526ee30a47cf"
    }
  }
]